Mariano Barbacid Montalbán-rekin lankidetzan egindako argitalpenak (16)

2024

  1. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 121, Núm. 36

2023

  1. Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 9

  2. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

    The Journal of clinical investigation, Vol. 133, Núm. 7

  3. Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity

    Cell, Vol. 186, Núm. 12, pp. 2628-2643.e21

2022

  1. KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors

    Molecular Oncology, Vol. 16, Núm. 17, pp. 3066-3081

  2. Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation

    Molecular Cell, Vol. 82, Núm. 18, pp. 3438-3452.e8

  3. The RAF/MEK clamp VS-6766 shows strong anti-tumor activity across multiple MAPK pathway alterations, with a preferential effect on KRAS G12V

    European Journal of Cancer, Vol. 174, pp. S18

2021

  1. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 30

  2. RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression

    Cancer Cell

2020

  1. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2019

  1. Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

    Cancer Cell, Vol. 35, Núm. 4, pp. 573-587.e6

  2. Effects of a Ketogenic Diet on [18F]FDG-PET Imaging in a Mouse Model of Lung Cancer

    Molecular Imaging and Biology, Vol. 21, Núm. 2, pp. 279-285

2018

  1. Afatinib restrains K-RAS-driven lung tumorigenesis

    Science Translational Medicine, Vol. 10, Núm. 44

  2. c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling

    Cancer Cell, Vol. 33, Núm. 2, pp. 217-228.e4

2014

  1. Reply: Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

    British Journal of Cancer

2013

  1. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

    British Journal of Cancer, Vol. 109, Núm. 4, pp. 926-933